FcRn antibody

Catalog No. ABIN1774762

Product Details anti-FcRn Antibody

Key Features:

• High-quality FcRn antibody (Clone ADM31) for the detection of FcRn.
• Highly specific for human FcRn, blocks the binding of human serum albumin.
• PBS-only, preservative free
• 15 PubMed references available for this FcRn antibody.

Target: FcRn (IgG receptor FcRn (FcRn))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This FcRn antibody is un-conjugated

Application: ELISA, Immunofluorescence (IF), Flow Cytometry (FACS), Cell-ELISA (cELISA), Functional Studies (Func)

Characteristics: based on recognition of the complete native protein expressed on transfected mammalian cells

Purification: Purified, Protein G

Immunogen: hFcRn

Clone: ADM31

Isotype: IgG2b lambda

Product Specific Information:

What can the FcRn antibody ABIN1774762 / ADM31 antibody be used for? This monoclonal mouse anti-FcRn antibody is unconjugated and is suitable for the detection of FcRn (Fc receptor) in human samples. The FcRn antibody is validated for Cell ELISA, ELISA, FACS and IF.

What validation data is available for this FcRn antibody / ADM31 antibody? 6 images for FACS and other applications are available. The product is cited in 15 PubMed publications. User our high quality product to reliably detect Fc receptor.

The MHC class I-like Fc receptor (FcRn) functions as an intracellular trafficking receptor, uniquely accountable for prolonging the serum half-life of IgG subclass antibodies and facilitating their passage across cellular barriers. Through these actions, FcRn significantly impacts various aspects of antibody biology and pathobiology. Its crucial role in regulating IgG pharmacokinetics has been exploited in the development of therapeutic antibodies and related biological treatments. Additionally, FcRn is involved in the transport of serum albumin, contributing to the improved pharmacokinetic characteristics of albumin-conjugated therapies. However, a lack of dependable serological tools targeting human FcRn has limited the comprehension of its functions and potential therapeutic uses.

Application Details

Application Notes:

• Flow cytometry: 1.2 μg/10^6 cells
• ELISA: 1:200 - 1:400
• CELISA: 1:200 - 1:400

For each application a titration should be performed to determine the optimal concentration.

Restrictions: For Research Use only

Handling

Buffer: PBS pH 7.2

Handling Advice: avoid repeated freezing and thawing

Storage: 4 °C

References for anti-FcRn antibody (ABIN1774762)

Gjølberg, Frick, Mester, Foss, Grevys, Høydahl, Jørstad, Schlothauer, Sandlie, Moe, Andersen: "Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life." in: Communications biology, Vol. 5, Issue 1, pp. 832, (2022) (PubMed).

Cines, Zaitsev, Rauova, Rux, Stepanova, Krishnaswamy, Sarkar, Kowalska, Zhao, Mast, Blumberg, McCrae, Poncz, Hubbard, Pyzik, Blumberg: "FcRn augments induction of tissue factor activity by IgG-containing immune complexes." in: Blood, Vol. 135, Issue 23, pp. 2085-2093, (2021) (PubMed).

Hubbard, Pyzik, Rath, Kozicky, Sand, Gandhi, Grevys, Foss, Menzies, Glickman, Fiebiger, Roopenian, Sandlie, Andersen, Sly, Baker, Blumberg: "FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex-driven autoimmunity." in: The Journal of experimental medicine, Vol. 217, Issue 10, (2021) (PubMed).

Bern, Nilsen, Ferrarese, Sand, Gjølberg, Lode, Davidson, Camire, Bækkevold, Foss, Grevys, Dalhus, Wilson, Høydahl, Christianson, Roopenian, Schlothauer, Michaelsen, Moe, Lombardi, Pinotti, Sandlie et al.: "An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics. ..." in: Science translational medicine, Vol. 12, Issue 565, (2021) (PubMed).

Casulleras, Flores-Costa, Duran-Güell, Alcaraz-Quiles, Sanz, Titos, López-Vicario, Fernández, Horrillo, Costa, de la Grange, Moreau, Arroyo, Clària: "Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis." in: Science translational medicine, Vol. 12, Issue 566, (2021) (PubMed).

Blumberg, Humphries, Jones, Pearce, Holgate, Hearn, Cheung, Mahmood, Del Tito, Graydon, Stolz, Bitonti, Purohit, de Graaf, Kacena, Andersen, Christianson, Roopenian, Hubbard, Gandhi, Lasseter, Pyzik et al.: "Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses. ..." in: Science advances, Vol. 5, Issue 12, pp. eaax9586, (2020) (PubMed).

Chung, Nguyen, Lin, Lafrance-Vanasse, Scales, Lin, Deng, Williams, Sperinde, Li, Zheng, Sukumaran, Tesar, Ernst, Fischer, Lazar, Prabhu, Song: "An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans." in: mAbs, Vol. 11, Issue 5, pp. 942-955, (2019) (PubMed).

Swiercz, Mo, Khare, Schneider, Ober, Ward: "Loss of expression of the recycling receptor, FcRn, promotes tumor cell growth by increasing albumin consumption." in: Oncotarget, Vol. 8, Issue 2, pp. 3528-3541, (2018) (PubMed).

Pyzik, Rath, Kuo, Win, Baker, Hubbard, Grenha, Gandhi, Krämer, Mezo, Taylor, McDonnell, Nienaber, Andersen, Mizoguchi, Blumberg, Purohit, Jones, Christianson, Lencer, Sandlie, Kaplowitz, Roopenian et al.: "Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury. ..." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 114, Issue 14, pp. E2862-E2871, (2018) (PubMed).

Grevys, Nilsen, Sand, Daba, Øynebråten, Bern, McAdam, Foss, Schlothauer, Michaelsen, Christianson, Roopenian, Blumberg, Sandlie, Andersen: "A human endothelial cell-based recycling assay for screening of FcRn targeted molecules." in: Nature communications, Vol. 9, Issue 1, pp. 621, (2018) (PubMed).

Roopenian, Christianson, Proetzel, Sproule: "Human FcRn Transgenic Mice for Pharmacokinetic Evaluation of Therapeutic Antibodies." in: Methods in molecular biology (Clifton, N.J.), Vol. 1438, pp. 103-14, (2017) (PubMed).

Foss, Grevys, Sand, Bern, Blundell, Michaelsen, Pleass, Sandlie, Andersen: "Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization." in: Journal of controlled release : official journal of the Controlled Release Society, Vol. 223, pp. 42-52, (2016) (PubMed).

Christianson, Sun, Akilesh, Pesavento, Proetzel, Roopenian: "Monoclonal antibodies directed against human FcRn and their applications." in: mAbs, Vol. 4, Issue 2, pp. 208-16, (2014) (PubMed).

Powner, McKenzie, Christianson, Roopenian, Fruttiger: "Expression of neonatal Fc receptor in the eye." in: Investigative ophthalmology & visual science, Vol. 55, Issue 3, pp. 1607-15, (2014) (PubMed).

Sand, Dalhus, Christianson, Bern, Foss, Cameron, Sleep, Bjørås, Roopenian, Sandlie, Andersen: "Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies." in: The Journal of biological chemistry, Vol. 289, Issue 24, pp. 17228-39, (2014) (PubMed).

Target Details for FcRn

Target: FcRn (IgG receptor FcRn (FcRn))

Abstract: FcRn Products

Synonyms: FCRN antibody, alpha-chain antibody, FcRn antibody, Fc fragment of IgG receptor and transporter antibody, Fc receptor, IgG, alpha chain transporter antibody, FCGRT antibody, Fcgrt antibody

Background: The MHC class I-like Fc receptor (FcRn) is an intracellular trafficking Fc receptor that is uniquely responsible for the extended serum half-life of antibodies of the IgG subclass and their ability to transport across cellular barriers. By performing these functions, FcRn affects numerous facets of antibody biology and pathobiology. Its critical role in controlling IgG pharmacokinetics has been leveraged for the design of therapeutic antibodies and related biologics. FcRn also traffics serum albumin and is responsible for the enhanced pharmacokinetic properties of albumin-conjugated therapeutics.
Synonyms: IgG receptor FcRn large subunit p51, Neonatal Fc receptor, FCGRT

UniProt: P55899

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process